Friday, 16 October 2026European Markets

NEXITY, EUROCOMMERCIAL, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - nexity (nxi.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
nexity (nxi.pa) €13.46 18.23% 8.59%
eurocommercial (ecmpa.as) €21.66 14.27% 1.73%
home invest be. (homi.br) €14.50 7.2% 3.64%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. nexity (nxi.pa)

18.23% forward dividend yield and 8.59% return on equity

nexity sa operates as a real estate company in europe and internationally. the company operates through development, services, and other activities divisions. it develops new homes and subdivisions; and new or refurbished office buildings, high-rises building, business parks, logistics facilities, retail property, hotels, and other industrial spaces. the company also provides property management services comprising rental management, sales and lettings, and condominium managing agent services, as well as manages serviced residences for students; distributes real estate products under the iselection and perl brands; offers insurance brokerage and asset management services; and real estate services, including rental management and property management services, consulting, and short-term rental of working spaces. in addition, it engages in the villes and projets, and pre-development urban regeneration projects; and investment activities. the company serves individual, corporate, institutional, and local authority clients. nexity sa was founded in 1995 and is headquartered in paris, france.

earnings per share

as for profitability, nexity has a trailing twelve months eps of €2.26.

pe ratio

nexity has a trailing twelve months price to earnings ratio of 5.96. meaning, the purchaser of the share is investing €5.96 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.59%.

revenue growth

year-on-year quarterly revenue growth grew by 5.1%, now sitting on 4.44b for the twelve trailing months.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, nexity's stock is considered to be overbought (>=80).

dividend yield

as maintained by morningstar, inc., the next dividend payment is on may 24, 2023, the estimated forward annual dividend rate is 2.5 and the estimated forward annual dividend yield is 18.23%.

more news about nexity.

2. eurocommercial (ecmpa.as)

14.27% forward dividend yield and 1.73% return on equity

eurocommercial properties n.v. is a euronext-quoted property investment company and one of europe's shopping centre specialists. founded in 1991, eurocommercial currently owns and operates 24 shopping centres in belgium, france, italy, and sweden with total assets of just over €3.8 billion.

earnings per share

as for profitability, eurocommercial has a trailing twelve months eps of €0.7.

pe ratio

eurocommercial has a trailing twelve months price to earnings ratio of 30.94. meaning, the purchaser of the share is investing €30.94 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.73%.

dividend yield

according to morningstar, inc., the next dividend payment is on jun 15, 2023, the estimated forward annual dividend rate is 3.1 and the estimated forward annual dividend yield is 14.27%.

volatility

eurocommercial's last week, last month's, and last quarter's current intraday variation average was a negative 0.10%, a positive 0.30%, and a positive 1.20%.

eurocommercial's highest amplitude of average volatility was 1.48% (last week), 1.47% (last month), and 1.20% (last quarter).

revenue growth

year-on-year quarterly revenue growth declined by 10.3%, now sitting on 268.39m for the twelve trailing months.

yearly top and bottom value

eurocommercial's stock is valued at €21.66 at 06:30 est, way under its 52-week high of €24.12 and way above its 52-week low of €19.26.

more news about eurocommercial.

3. home invest be. (homi.br)

7.2% forward dividend yield and 3.64% return on equity

home invest belgium s.a. operates as a real estate investment company in belgium. it primarily invests in residential properties. as of december 31, 2008, the company's real estate portfolio consisted of 992 rental units with a total rentable space of approximately 111,091 square meters. the company was formerly known as home invest and changed its name to home invest belgium s.a. in may 1999. home invest belgium s.a. was founded in 1980 and is based in brussels, belgium.

earnings per share

as for profitability, home invest be. has a trailing twelve months eps of €0.67.

pe ratio

home invest be. has a trailing twelve months price to earnings ratio of 21.64. meaning, the purchaser of the share is investing €21.64 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.64%.

more news about home invest be..

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com